Finally, serum concentrations of metalloproteinase (MMP)-1/tissue inhibitor of matrix metalloproteinase (TIMP)-1, MMP-2/TIMP-2 and MMP-9/TIMP-2 ratios, found to be deregulated in MS patients [33], were also quantified as indicators of MMPs activation (Table 4). This evidence concerns the gene MMP1 and myeloid sarcoma.